ioner's Docket No. <u>MPI00-535OMNICN1M</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Fraser, Christopher C, et al					
Application No.:	10/741,790	Group No.:	1646			
Filed:	December 19, 2003	Examiner:	Not Yet Assigned			
For:	NOVEL GENES ENCODING	G PROTEIN	NS HAVING PROGNOSTIC,			
	DIAGNOSTIC, PREVENTIVE, THERAPEUTIC, AND OTHER USES					

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT TRANSMITTAL

- 1. Transmitted herewith for this application are:
 - a. This Amendment Transmittal (2 pages in duplicate);
 - b. Second Preliminary Amendment (11 pages);
 - c. Associate Power of Attorney (2 pages) and Appendix A Statement of Limited Recognition under 37 CFR §10.9(b) for Mario Cloutier (1 page);
 - d. Statement of Limited Recognition under 37 CFR §10.9(b) for Mario Cloutier (1 page);
 - e. Return Receipt Postcard.

STATUS

2. Applicant is other than a small entity.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"
Mailing Label No.

TRANSMISSION transmitted by facsimile to the Patent and Trademark Office

Alm

Signature

Sean Hunziker

Date: October 29, 2004

(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI00-535OMNICN1M

FEE FOR CLAIMS

3. The fee for claims (37 C.F.R. 1.16(b)-(d)) has been calculated as shown below:

(Col. 1) Claims Remaining After Amendment		(Col. 2)		(Col. 3)	OTHER THE			
		Highest No. Previously Paid For		Present Extra	Rate		Addit. Fee	
Total	20	Minus	20	=	0	\$18.00	=	\$0.00
Indep.	3	Minus	3	=	0	\$88.00	=	\$0.00
First Presentation of Multiple Dependent Claims			0			\$300.00	=	\$0.00
						Total Addit. Fee		\$0.00

Total additional fee for claims required

\$0.00

FEE DEFICIENCY

5. Applicant believes there is no fee due with this request. If any additional extension and/or fee is required, charge Account No. 501668.

If any additional fee for claims is required, charge Account No. 501668.

6. Correspondence Address
Direct all future correspondence to:

Customer Number 30405

OR

Intellectual Property Department MILLENNIUM PHARMACEUTICALS, INC.

40 Landsdowne Street Cambridge, MA 02139

October 29, 2004

MILLENNIUM PHARMACEUTICALS, INC.

Эy

Mario Cloutier

Limited Recognition Under 37 C.F.R. §10.9(b)

40 Landsdowne Street

Cambridge, MA 02139 Telephone - 617-577-3522

Facsimile - 617-551-8820